Share

February 2018; 4 (1) The HelixOpen Access

2017 Year in Review and Message from the Editors to Our Reviewers

Stefan M. Pulst, Nicholas Elwood Johnson, Massimo Pandolfo, Raymond P. Roos, Jeffery M. Vance
First published February 20, 2018, DOI: https://doi.org/10.1212/NXG.0000000000000221
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
332

Share

Article Information

vol. 4 no. 1 e221
DOI: 
https://doi.org/10.1212/NXG.0000000000000221
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2376-7839
History: 
  • Received January 11, 2018
  • Accepted in final form January 11, 2018
  • First Published February 20, 2018.
Copyright & Usage: 
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Stefan M. Pulst, MD, Dr med, Editor,
    2. Nicholas Elwood Johnson, MD, Deputy Editor,
    3. Massimo Pandolfo, MD, FAAN,
    4. Raymond P. Roos, MD, FAAN and
    5. Jeffery M. Vance, MD, PhD, Associate Editors
  1. Stefan M. Pulst, MD, Dr med, Editor,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Cerebellum, NeuroMolecular Medicine, Experimental Neurology, Neurogenetics, Nature Clinical Practice Neurology Editor-in-Chief: Neurology: Genetics

    Patents:

    1. Nucleic acids encoding ataxin-2 binding proteins; Nucleic acid encoding Schwannomin-binding-proteins and products related thereto; Transgenic mouse expressing a polynucleotide encoding a human ataxin-2 polypeptide; Methods of detecting spinocerebellar ataxia-2 nucleic acids; Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto; Shwannomin-binding-proteins; Compositions and methods for spinocerebellar ataxia

    Publishing Royalties:

    1. The Ataxias (Churchill Livingston, 2007), Genetics in Neurology (ANN Press, 2005), Genetics of Movement Disorders (Academic Press, 2003), Neurogenetics (Oxford University Press, 2000), Molecular Genetic Testing in Neurology, 2nd - 5th (AAN Press, 1996)

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Ataxion Therapeutics

    Speakers' Bureaus:

    1. Athena Diagnostics, Inc.

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) 2010-2012 National Institutes of Health (RC1NS068897): CLINICAL RESEARCH CONSORTIUM FOR SPINOCEREBELLAR ATAXIAS, 9/1/2009-8/31/2012 (Principal Investigator of genomics core and site PI). (2) 2010-2013 National Institutes of Health (RC4NS073009): Drug discovery for Spinocerebellar ataxia type 2 (SCA2). 9/1/2010-8/31/2013 (Principle Investigator, Co-PI, D. Scoles). (3) 2013-2015 National Institutes of Health (R21NS081182): Antisense oligonucleotides for the treatment of spinocerebellar ataxia type 2. 07/01/2013 to 06/30/2015 (Co- PI with D. Scoles). (4) 2013-2016 National Institutes of Health (R21NS079852): Identification of a mutation causing Purkinje cell degeneration in the rat. 03/01/2013 to 02/28/2016. (Principle Investigator). (5) 2014-2021 National Institutes of Health (RO1NS33123): Spinocerebellar ataxia type 2: gene and gene product. 9/30/14-6/30/2021. (Principal Investigator).

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Ataxia foundation (mentor for fellowship award)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License fee payments, Technology or Inventions:

    1. Cedars-Sinai Medical Center

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Nicholas Elwood Johnson, MD, Deputy Editor,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neurology: Genetics, Associate Editor, 1.5 years

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) AMO Pharma, (2) AveXis

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Ionis Pharmaceuticals, (2) Biogen Idec, (3) Valerion Therapeutics, (4) Cytokinetics, (5) Acceleron

    Research Support, Government Entities:

    1. (1) NINDS, 1K23NS091511-01, 2 years

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Muscular Dystrophy Association, (2) Myotonic Dystrophy Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Massimo Pandolfo, MD, FAAN,
    4. Scientific Advisory Boards:

    1. (1) Apopharma, DSMB and consulting (2) Voyager Therapeutics, Scientific Advisory Board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Acta Neurologica Belgica, Editorial Board Member, 2011- (2) Orphanet Journal of Rare Diseases, Editorial Board Member, 2013- (3) Neurology Genetics, Associate Editor, 2015-

    Patents:

    1. (1) Direct molecular diagnosis of Friedreich?s ataxia. M. Pandolfo, L. Montermini, M.D. L. Molto, M. Koenig, V. Campuzano, M. Cossee. US patent (2000) 6, 150, 091, WO patent (1997) 9705234.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Biomarin (2) UCB

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biomarin

    Research Support, Government Entities:

    1. (1) Fonds National de la Recherche Scientifique (Belgium)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Offrez-moi-la-lune (2) Friedreich's Ataxia Research Alliance (3) Association Belge contre les Maladies neuro-Musculaires

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. (1) Friedreich's ataxia diagnostic test, Athena Diagnostics, since 1997

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Raymond P. Roos, MD, FAAN and
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Virology, Editorial Board, 2013-present Neurology Genetics, Associate Editor, 2015-present MedLink, Senior Associate Editor, 2001-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NINDS, NIH, 1 R21 NS078142-01 (PI) 3/15/12-1/31/15

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (i) Ralph and Marian Falk Medical Research Trust (ii) Judith and Jean Pape Adams Charitable Foundation (iii) ALS Association (iv) Chicago Biomedical Consortium

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. Ionis Pharmaceuticals, 2014-present Stock/Stock Options, Medical Equipment & Materials: (i) Merck (ii) Amgen (iii) Express Scripts

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Jeffery M. Vance, MD, PhD, Associate Editors
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. NETPR, Department of Defense, review section. NIH, Meetings

    Editorial Boards:

    1. America Journal of Neurodegenerative Diseases, editorial board, 3 year Neurology Genetics, Associate Editor, 2 year

    Patents:

    1. 1) method of detecting Charcot-Marie-Tooth disease type 2A 2) TRPC6 involved in glomerulonephritis 3) Methods for identifying an individual at increased risk of developing coronary artery disease

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH/NINDS 5P50NS071674 PI, 16y DOD/ W81XWH-14-1-0097 PI, 2y NIH/NINDS 1R25NS090624 PI, 2y

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Hussman Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. Royalty, Duke University, 7y for CMT2A with Athena

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (S.M.P., N.E.J.), University of Utah, Salt Lake City; Hôpital Erasme (M.P.), Université Libre de Bruxelles, Belgium; University of Chicago Medical Center (R.P.R.); and University of Miami (J.M.V.), Coral Gables, FL.
View Full Text

Article usage

Article usage: February 2018 to December 2020

AbstractFullPdfSource
Feb 2018024215Highwire
Mar 2018121621Highwire
Apr 201809011Highwire
May 20180984Highwire
Jun 20180898Highwire
Jul 20180723Highwire
Aug 20181776Highwire
Sep 201807219Highwire
Oct 20180649Highwire
Nov 201808615Highwire
Dec 2018010919Highwire
Jan 201947923Highwire
Feb 201921097Highwire
Mar 2019016322Highwire
Apr 2019328913Highwire
May 2019219514Highwire
Jun 2019424812Highwire
Jul 2019134811Highwire
Aug 2019076510Highwire
Sep 201907175Highwire
Oct 201906082Highwire
Nov 201903975Highwire
Dec 201901955Highwire
Jan 20200228Highwire
Feb 20200259Highwire
Mar 2020093Highwire
Apr 20201265Highwire
May 20201176Highwire
Jun 202011910Highwire
Jul 20201126Highwire
Aug 20200176Highwire
Sep 20200304Highwire
Oct 20200262Highwire
Nov 20200227Highwire
Dec 20201137Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.ng.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement